ValiRx Plc, a biopharmaceutical company, engages in the research and development of technologies and products in oncology therapeutics and diagnostics in the United Kingdom. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology is involved in silencing or freezing rebellious genes, which cause cancer and various neurological problems. The company’s lead drug candidates in late stage pre-clinical development include VAL101, a compound based on GeneICE technology that acts to target the Bcl-2 gene, a protein that inhibits the process of apoptosis; and VAL201, a peptide for the treatment of hormone refractory prostate cancer, and other indications of hormone induced unregulated growth, including endometriosis. It also offers ValBiomarkers that target sites for drugs to treat cancer, and predictive markers of disease progression; and reagent-based home screening tests to detect levels or the presence of a range of biological markers under the brand SELFCheck. Valirx Plc is based in London, the United Kingdom.
valirx plc (VAL:London)
24 Greville Steet
London, EC1N 8SS
Phone: 44 20 3008 4416
Fax: 44 20 3008 4415www.valirx.com
|No competitor information is available for VAL.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.